Pan Hammarström Lab

We focus on two main areas of research:
Primary immunodeficiency and B cell malignancy

Qiang Pan Hammarström group members 2023
Qiang Pan Hammarström Lab members 2023 Photo: N/A

Current projects:

Regulation of immunoglobulin class switch recombination in human B cells

This project is aimed at understanding the complex molecular mechanisms involved in DNA editing, repair and recombination during immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM) and their involvement in the pathophysiological processes leading to immunodeficiency, genome instability and cancer development in humans.

Video explaining non-homologous end joining in class switch recombination

Induced pluripotent stems cells a platform for personalized diagnosis and therapy in patients with primary immunodeficiency

microscopy image
An iPSC colony derived from IgAD patient's fibroblast cells. Photo: Qiang Pan-Hammarström's group

The project is aimed at reprogramming the fibroblasts derived from primary immunodeficiency patients into pluripotent stem (iPS) cells and re-differentiating these iPS cells into antibody-producing B cells. If successful, this study will provide a methodological platform for the study of human B cell development and for development of new therapies aiming at editing genes/cells in patients with a variety of other primary immunodeficiency diseases.

Discovery of therapeutic targets in B cell lymphoma by next generation sequencing

illustration in coulour showing notch signalling, cell migration, immune escape etc, in red and blue
Altered pathways in Hepatitis B virus - associated in diffuse large B cell lymphoma. Illustration: Qiang Pan Hammarström's group

The project is aimed at identifying potentially treatable molecular targets in mature B cell lymphomas (with focus on diffuse large B cell lymphoma, follicular lymphoma and mantle cell lymphoma) by applying high-throughput, next generation-sequencing technologies such as whole genome and whole exome sequencing, immune repertoire sequencing, RNA sequencing and single-cell RNA sequencing. The multiomic sequencing data will be further integrated with clinical data as well as functional assays to identify genes/pathways that can be used for disease classification and prediction and for the development of new targeted therapy.

Antibody therapy against COVID-19

The project is aimed at establishing a passive immunotherapy against coronavirus COVID19. To reach this overall goal, we will obtain blood samples from convalescent donors, i.e. people who have recovered from the infection, to isolate antibodies that can be used to prevent and to treat the disease. 

Group members

Qiang Pan Hammarström

Professor and Group leader
C2 Department of Medical Biochemistry and Biophysics

Harold Marcotte

C2 Department of Medical Biochemistry and Biophysics

Hassan Abolhassani

Assistant Professor of Clinical Immunology
C2 Department of Medical Biochemistry and Biophysics

Likun Du

Laboratory coordinator
C2 Department of Medical Biochemistry and Biophysics

Weicheng Ren

C2 Department of Medical Biochemistry and Biophysics

Fanglei Zuo

Affiliated to research
C2 Department of Medical Biochemistry and Biophysics
C2 Department of Medical Biochemistry and Biophysics

Hui Wan

PhD Student
C2 Department of Medical Biochemistry and Biophysics

Rui Sun

PhD Student
C2 Department of Medical Biochemistry and Biophysics

Yating Wang

PhD Student
C2 Department of Medical Biochemistry and Biophysics

Mingyu Yang

PhD Student
C2 Department of Medical Biochemistry and Biophysics

Stylianos Vlachiotis

PhD Student
C2 Department of Medical Biochemistry and Biophysics


Click here to view list of alumni

Selected latest publications

Mesoscale DNA feature in antibody-coding sequence facilitates somatic hypermutation.
Wang Y, Zhang S, Yang X, Hwang JK, Zhan C, Lian C, Wang C, Gui T, Wang B, Xie X, Dai P, Zhang L, Tian Y, Zhang H, Han C, Cai Y, Hao Q, Ye X, Liu X, Liu J, Cao Z, Huang S, Song J, Pan-Hammarström Q, Zhao Y, Alt FW, Zheng X, Da LT, Yeap LS, Meng FL
Cell 2023 May;186(10):2193-2207.e19

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1.
Zuo F, Sun R, Abolhassani H, Du L, Wang Y, Vlachiotis S, Bertoglio F, Schubert M, Rezaei N, Chavoshzadeh Z, Guerra C, Cavalli A, Andréll J, Kumagai-Braesch M, Xue Y, Cao Y, Hust M, Robbiani DF, Xie XS, Hammarström L, Marcotte H, Pan-Hammarström Q
Lancet Reg Health West Pac 2023 Apr;33():100762

DNA repair mechanisms that promote insertion-deletion events during immunoglobulin gene diversification.
Hao Q, Zhan C, Lian C, Luo S, Cao W, Wang B, Xie X, Ye X, Gui T, Voena C, Pighi C, Wang Y, Tian Y, Wang X, Dai P, Cai Y, Liu X, Ouyang S, Sun S, Hu Q, Liu J, Ye Y, Zhao J, Lu A, Wang JY, Huang C, Su B, Meng FL, Chiarle R, Pan-Hammarström Q, Yeap LS
Sci Immunol 2023 Mar;8(81):eade1167

Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome.
Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du L, Aranda-Guillén M, Sardh F, Zuo F, Zhang P, Marcotte H, Marr N, Khan T, Ata M, Al-Ali F, Pescarmona R, Belot A, Béziat V, Zhang Q, Casanova JL, Kämpe O, Zhang SY, Hammarström L, Pan-Hammarström Q
J Clin Immunol 2022 Apr;42(3):471-483

A single-cell atlas of diffuse large B cell lymphoma.
Ye X, Wang L, Nie M, Wang Y, Dong S, Ren W, Li G, Li ZM, Wu K, Pan-Hammarström Q
Cell Rep 2022 Apr;39(3):110713

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, Sammartino JC, Sun R, Vlachiotis S, Bergami F, Kumagai-Braesch M, Andréll J, Zhang Z, Xue Y, Wenzel EV, Calzolai L, Varani L, Rezaei N, Chavoshzadeh Z, Baldanti F, Hust M, Hammarström L, Marcotte H, Pan-Hammarström Q
Nat Commun 2022 May;13(1):2670

Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19.
Abolhassani H, Delavari S, Landegren N, Shokri S, Bastard P, Du L, Zuo F, Hajebi R, Abolnezhadian F, Iranparast S, Modaresi M, Vosughimotlagh A, Salami F, Aranda-Guillén M, Cobat A, Marcotte H, Zhang SY, Zhang Q, Rezaei N, Casanova JL, Kämpe O, Hammarström L, Pan-Hammarström Q
J Allergy Clin Immunol 2022 Nov;150(5):1059-1073

Mucosal IgA against SARS-CoV-2 Omicron Infection.
Zuo F, Marcotte H, Hammarström L, Pan-Hammarström Q
N Engl J Med 2022 Nov;387(21):e55

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.
De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Cassaniti I, Percivalle E, Lorenzi JCC, Mazzola F, Magrì D, Michalcikova T, Haviernik J, Honig V, Mrazkova B, Polakova N, Fortova A, Tureckova J, Iatsiuk V, Di Girolamo S, Palus M, Zudova D, Bednar P, Bukova I, Bianchini F, Mehn D, Nencka R, Strakova P, Pavlis O, Rozman J, Gioria S, Sammartino JC, Giardina F, Gaiarsa S, Pan-Hammarström Q, Barnes CO, Bjorkman PJ, Calzolai L, Piralla A, Baldanti F, Nussenzweig MC, Bieniasz PD, Hatziioannou T, Prochazka J, Sedlacek R, Robbiani DF, Ruzek D, Varani L
Nature 2021 May;593(7859):424-428

Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas.
Ye X, Ren W, Liu D, Li X, Li W, Wang X, Meng FL, Yeap LS, Hou Y, Zhu S, Casellas R, Zhang H, Wu K, Pan-Hammarström Q
J Exp Med 2021 Feb;218(2):


Full list of publications

Looking for a postdoc position?

Postdoc positions on B cell development, immunogenetics, COVID19 and cancer genetics available.

For details contact: Prof. Pan-Hammarström

Research techniques

  • DNA sequencing, including whole exome and whole genome sequencing

  • Gene expression analysis including real time PCR and RNAseq/transcriptome analysis

  • B and T cell functional assays

  • Generating iPSCs

  • Gene editing using the CRISPR/Cas9 system

Related news

Content reviewer: